Washed Microbiota Transplantation for Diabetic Gastroparesis

Trial details

Who runs it

The Second Hospital of Nanjing Medical University

Trial code

NCT06340217

Record updated

5 August 2026

Original description

This is a randomized controlled trial to explore the efficacy and safety of washed microbiota transplantation (WMT) for diabetic gastroparesis (DGP) patients.Read full original descriptionShow less

The Efficacy and Safety of WMT in the Treatment of Diabetic Gastroparesis: A Multicenter, Randomized, Double-blind, Placebo-controlled Study

This is a randomized controlled trial to explore the efficacy and safety of washed microbiota transplantation (WMT) for diabetic gastroparesis (DGP) patients.

Inclusion: Subjects must meet all of the following inclusion criteria to enter the study:; Diagnosed with diabetes for over 1 year; Accompanied by symptoms such as abdominal bloating, early satiety, persisting for at least 3 months, with a GCSI Total Score greater than/equal to 2.3; Objective evidence of delayed gastric emptying within the past 3 months, including but not limited to scintigraphic gastric emptying or gastric ultrasound; Upper gastrointestinal obstructive lesions were ruled out by imaging or endoscopic examination within the past 3 months; Males and nonpregnant, non-breastfeeding females who are aged more than 18 years and sign the informed consent form; The subject or his/her legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.

Exclusion: Have any upper gastrointestinal pathology other than diabetic gastroparesis that would require therapy other than that provided in this trial; Have a prior history of gastric surgery, including but not limited to gastric bypass, gastrectomy, gastric banding, pyloroplasty, fundoplication, or vagotomy in past 1 year; Have been using medications affecting gastrointestinal motility, such as GLP-1 agonists; Have any organic/neurological disease that is suspected to be causing gastroparesis, other than diabetes; Have a history of medication that regulate intestinal microbiome in last 48 hours; Have preexisting hepatic disease that meets Child-Pugh Class B (moderate; total score 7 to 9 points) or C (severe; total score 10 to 15 points); Have infectious diseases such as active hepatitis (requiring long-term use of drugs), HIV or active tuberculosis; Have a history of drug abuse, alcoholism (defined as consuming more than 14 units per week, with 1 unit equivalent to 360 mL of beer, 45 mL of 40% alcohol, or 150 mL of wine), or substance misuse; Other significant systemic illnesses, such as malignant tumors; Have any of the following abnormalities in cardiac function and cardiac performance:; Cardiac function rating≥Ⅲ according to New York Heart Association (NYHA); New myocardial infarction or unstable angina pectoris within 6 months; Electrocardiogram indicated prolonged QTc interval (male QTc≥450ms, female QTc≥470ms); requiring drug intervention (more than Ⅱ atrioventricular block); Kidney disease with KDIGO stage 3b (GFR<45 ml/min/1.73m2) or above; Subjects meeting any of the following exclusion criteria must be excluded from the study:; Subjects who:; Have contraindications for intestinal tubing; Have serious diabetic complications need immediately be dealt, such as diabetic ketoacidosis; Have poor lung function and those deemed by the investigator to be affected by the study treatment, such as during COPD exacerbations; Have other situations in which the investigator deems it inappropriate to participate in this study.

ClinicalTrials.gov NCT06340217